Citius Pharmaceuticals CTXR
NASDAQ CTXR
$0.60 +0.00 (+0.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Citius Pharmaceuticals (CTXR) Cash from Investing Activities (2021 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly Cash from Investing Activities came in at -$600000.0 in Q1 2026, up 86.36% on a QoQ basis from -$4.4 million in Q4 2025.

Citius Pharmaceuticals (CTXR) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has 3 years of Cash from Investing Activities data on file, last reported at -$600000.0 in Q1 2026.

  • Quarterly Cash from Investing Activities changed N/A year-over-year to -$600000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.0 million (changed N/A YoY) and the FY2025 annual result came in at -$5.8 million, down 15.0% from the prior year.
  • Cash from Investing Activities climbed to -$600000.0 in Q1 2026, from -$4.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$600000.0 in Q1 2026 to a low of -$4.4 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 329.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -49.35 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -363.46 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -3.17 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 24.51 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -229.72 Mn
10 Citius Pharmaceuticals 15.71 Mn 15.71 Mn 1.00 Mn -2.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -600,000.00
Mar 31, 2026 -600,000.00
Dec 31, 2025 -4.40 Mn
Dec 31, 2025 -4.40 Mn
Sep 30, 2021 -40.00 Mn
Sep 30, 2021 -40.00 Mn